 Acute Coronary Syndrome
"Acute Coronary Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Descriptor ID |
D054058
|
| MeSH Number(s) |
C14.280.647.124 C14.907.585.124
|
| Concept/Terms |
Acute Coronary Syndrome- Acute Coronary Syndrome
- Acute Coronary Syndromes
- Coronary Syndrome, Acute
- Coronary Syndromes, Acute
- Syndrome, Acute Coronary
- Syndromes, Acute Coronary
|
Below are MeSH descriptors whose meaning is more general than "Acute Coronary Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Acute Coronary Syndrome".
This graph shows the total number of publications written about "Acute Coronary Syndrome" by people in this website by year, and whether "Acute Coronary Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 4 | 0 | 4 | | 2008 | 7 | 0 | 7 | | 2009 | 13 | 0 | 13 | | 2010 | 7 | 0 | 7 | | 2011 | 8 | 0 | 8 | | 2012 | 14 | 2 | 16 | | 2013 | 17 | 2 | 19 | | 2014 | 17 | 1 | 18 | | 2015 | 11 | 2 | 13 | | 2016 | 10 | 1 | 11 | | 2017 | 13 | 1 | 14 | | 2018 | 14 | 0 | 14 | | 2019 | 16 | 0 | 16 | | 2020 | 15 | 2 | 17 | | 2021 | 7 | 2 | 9 | | 2022 | 14 | 0 | 14 | | 2023 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Acute Coronary Syndrome" by people in Profiles.
-
Suc G, Schwartz GG, Goodman SG, Jukema JW, Manvelian G, Poulouin Y, Pordy R, Scemama M, Szarek M, Steg PG. Effect of alirocumab on cataracts in patients with acute coronary syndromes. BMC Ophthalmol. 2023 Jun 16; 23(1):279.
-
Canonico ME, Hess CN, Cannon CP. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show? Curr Atheroscler Rep. 2023 07; 25(7):381-389.
-
Steg PG, Szarek M, Valgimigli M, Islam S, Zeiher AM, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Gotcheva N, Harrington RA, Jukema JW, Kim HS, Kim SH, Morais J, Pordy R, Scemama M, White HD, Schwartz GG. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. Can J Cardiol. 2023 10; 39(10):1315-1324.
-
Kato ET, Morrow DA, Guo J, Berg DD, Blazing MA, Bohula EA, Bonaca MP, Cannon CP, de Lemos JA, Giugliano RP, Jarolim P, Kempf T, Kristin Newby L, O'Donoghue ML, Pfeffer MA, Rifai N, Wiviott SD, Wollert KC, Braunwald E, Sabatine MS. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J. 2023 01 21; 44(4):293-300.
-
Damluji AA, Forman DE, Wang TY, Chikwe J, Kunadian V, Rich MW, Young BA, Page RL, DeVon HA, Alexander KP. Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association. Circulation. 2023 01 17; 147(3):e32-e62.
-
Amin G, Massoud G, Fares S, Booz GW, Zouein FA. Colchicine and Acute Coronary Syndromes: A New Trick for an Old Drug? J Cardiovasc Pharmacol. 2022 11 01; 80(5):631-632.
-
Landmesser U, McGinniss J, Steg PG, Bhatt DL, Bittner VA, Diaz R, Dilic M, Goodman SG, Jukema JW, Loy M, Pecin I, Pordy R, Poulsen SH, Szarek M, White HD, Schwartz GG. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. Eur J Prev Cardiol. 2022 10 20; 29(14):1842-1851.
-
Azzalini L, Seth M, Sukul D, Valle JA, Daher E, Wanamaker B, Tucciarone MT, Zaitoun A, Madder RD, Gurm HS. Trends and outcomes of percutaneous coronary intervention during the COVID-19 pandemic in Michigan. PLoS One. 2022; 17(9):e0273638.
-
Moriarty PM, Steg PG, McGinniss J, Zeiher AM, White HD, Manvelian G, Pordy R, Loy M, Jukema JW, Harrington RA, Gray JV, Gorby LK, Goodman SG, Diaz R, Bittner VA, Bhatt DL, Szarek M, Schwartz GG. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. J Clin Lipidol. 2022 Sep-Oct; 16(5):747-756.
-
Hagstr?m E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|